Skip to main content

Table 3 Cox proportional hazard models of recurrence-free and overall survival among the retrospective stage III cohort

From: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

  Univariate Hazard Model
Recurrence-Free Survival Overall Survival
HR 95% CI P-value HR 95% CI P-value
NY-ESO-1 Vaccine 0.555 (0.374, 0.822) 0.0034 0.507 (0.310, 0.831) 0.007
Thickness (1 mm) 1.079 (1.044, 1.116) < 0.0001 1.101 (1.062, 1.141) < 0.0001
Ulceration Absent 1    1   
Present 2.206 (1.490, 3.266) < 0.0001 2.185 (1.336, 3.573) 0.0019
Undetermined 1.079 (0.600, 1.940) 0.8002 0.953 (0.413, 2.196) 0.9093
Age (1 year) 1.015 (1.002, 1.027) 0.0201 1.025 (1.008, 1.042) 0.0033
AJCC Stage IIIA 1    1   
IIIB 1.141 (0.730, 1.783) 0.5627 1.005 (0.643, 1.570) 0.9842
IIIC 1.795 (1.130, 2.850) 0.0132 1.457 (0.915, 2.319) 0.1129
  Multivariate Hazard Model
Recurrence-Free Survival Overall Survival
HR 95% CI P-value HR 95% CI P-value
NY-ESO-1 Vaccine 0.454 (0.301, 0.685) 0.0002 0.403 (0.269, 0.604) < 0.0001
AJCC Stage IIIA 1 (0.561, 1.370)   1   
IIIB 1.225 (0.783, 1.916) 0.3744 1.028 (0.658, 1.608) 0.9026
IIIC 2.348 (1.452, 3.797) 0.0005 1.792 (1.114, 2.883) 0.0161